Technology | June 23, 2009

AccessClosure Launches First True 5 French Vascular Closure Device

June 23, 2009 – AccessClosure yesterday launched its newest addition to the Mynx Vascular Closure family, the Mynx M5, which can be delivered directly through a small 5 Fr. cardiovascular sheath without enlarging the arterial hole or traumatizing the surrounding tissue in the process.

This “artery-friendly” approach also benefits hospitals, as the M5 eliminates the need for a sheath exchange, which saves procedure time and expense, the company said. Typically, procedural sheaths that are 5 Fr. in size are used in diagnostic coronary and peripheral catheterizations. The U.S. 5 Fr. closure market is estimated at nearly $200 million annually.

“Before the Mynx M5, existing closure devices required the physician to create a larger hole in the artery just to seal it in diagnostic cases,” explains Dharmesh Patel, M.D., FACC, a diagnostic cardiologist from Memphis Heart Clinic in Memphis, Tenn. “The M5 is the first device that specifically addresses the primary clinical need for the 5 Fr. market, which is to reliably close the puncture site without enlarging it first. This is particularly useful in my practice allowing patients to ambulate quicker with greater safety and tolerability.”

The Mynx Vascular Closure Device was first approved by the FDA for 6 Fr. and 7 Fr. cardiovascular procedures in May 2007. Since its full market release, the Mynx has been used in more than 225,000 patients in more than 700 hospitals nationwide.

Designed with the patient in mind, the Mynx offers a new solution to help minimize the discomfort commonly associated with vascular closure due to its unique deployment method and novel sealant material, the company said. Previous closure devices have used metal or animal-based implants to seal the arterial hole left after a cardiovascular procedure. By contrast, the Mynx uses a soft, bio-absorbable polymer material. This sealant material, polyethylene glycol (PEG), has been used safely for more than a decade in a wide range of medical products such as gel caps and eye drops.

During the closure procedure, the sealant is placed gently over the arterial puncture area. The sponge-like sealant immediately expands three to four times its original size by rapidly absorbing blood around the puncture site, which immediately stops the bleeding and seals the artery. The sealant then dissolves naturally within 30 days, leaving nothing behind inside, or on top of, the artery.

For more information:

Related Content

Essential Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for its large bore Manta Vascular Closure Device. It is designed to close large puncture sites in the femoral artery from larger sized transcatheter devices, including the Impella heart pump, endovascular stent grafts and transcatheter valves.
Technology | Vascular Closure Devices | April 03, 2019
April 3, 2019 — Essential Medical Inc. received U.S.
FDA Approves Vascade MVP Vascular Closure System
Technology | Vascular Closure Devices | December 20, 2018
Cardiva Medical Inc. announced the company has received premarket approval (PMA) from the U.S. Food and Drug...
PerQseal Large Bore Closure Device Launches in Europe
News | Vascular Closure Devices | November 21, 2018
Vivasure Medical Ltd. recently announced the European launch of the PerQseal closure device for large-bore...
Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
Overlay Init